Geron to Host Analyst and Investor Event on December 10, 2018
November 28 2018 - 5:30PM
Geron Corporation (Nasdaq: GERN) today announced that the Company’s
analyst and investor event will take place in New York, N.Y., on
Monday, December 10, 2018. Management will be joined by clinical
investigators from both IMerge and IMbark who will reprise oral
presentations from the 60th American Society of Hematology (ASH)
Annual Meeting occurring in early December, as well as discuss the
unmet medical need in hematologic myeloid malignancies. The event
will begin at 8:00 a.m. ET.
Azra Raza, M.D., Chan Soon-Shiong Professor of Medicine and
Director of the MDS Center in New York, will review data from Part
1 of the ongoing Phase 2/3 IMerge clinical trial of the telomerase
inhibitor imetelstat in patients with lower risk myelodysplastic
syndromes, including more mature efficacy and safety data from the
combined initial and expansion cohorts presented at ASH.
John Mascarenhas, M.D., Associate Professor of Medicine in the
Myeloproliferative Disorders Program of the Tisch Cancer Institute,
Division of Hematology/Oncology at the Icahn School of Medicine at
Mount Sinai, will review data from IMbark, the ongoing Phase 2
clinical trial of imetelstat in patients with Intermediate-2 or
High-risk myelofibrosis, including more mature data from the
extension phase of IMbark presented at ASH, including median
overall survival.
Analysts and investors in attendance will be able to ask
questions of the investigators during the question and answer
session following the presentations. In addition, the Company will
also discuss its development plans for imetelstat, including the
start of the Phase 3 portion of IMerge by mid-year 2019.
A live audio webcast of the event will be available on Geron’s
website, www.geron.com/investors/events. If you are unable to
listen to the live event, an archived webcast of the event will be
available on the Company’s website for 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on
the development and potential commercialization of a first-in-class
telomerase inhibitor, imetelstat, in hematologic myeloid
malignancies. For more information about Geron, visit
www.geron.com.
Use of Forward-Looking Statements
Except for the historical information contained herein, this
press release contains forward-looking statements made pursuant to
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such statements,
include, without limitation, those regarding that the Phase 3
portion of IMerge will begin by mid-year 2019 and other statements
that are not historical facts, constitute forward-looking
statements. These statements involve risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. These risks and uncertainties, include,
without limitation, risks and uncertainties related to: (i) whether
regulatory authorities permit the further development of imetelstat
on a timely basis, or at all, to enable patient screening and
enrollment of the Phase 3 portion of IMerge to begin by mid-year
2019; (ii) whether imetelstat is safe and efficacious, and whether
any past or future efficacy or safety results may cause the
benefit-risk profile of imetelstat to become unacceptable; and
(iii) whether the transition of the imetelstat program from Janssen
Biotech, Inc. to the Company proceeds on a timely basis to enable
the Phase 3 portion of IMerge to begin by mid-year
2019. Additional information on the above risks and
uncertainties and additional risks, uncertainties and factors that
could cause actual results to differ materially from those in the
forward-looking statements are contained in Geron’s periodic
reports filed with the Securities and Exchange
Commission under the heading “Risk Factors,” including Geron’s
quarterly report on Form 10-Q for the quarter ended September
30, 2018. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made, and the
facts and assumptions underlying the forward-looking statements may
change. Except as required by law, Geron disclaims any obligation
to update these forward-looking statements to reflect future
information, events or circumstances.
CONTACT:
Suzanne MessereInvestor and Media
Relationsinvestor@geron.commedia@geron.com
CG Capital877-889-1972
Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2023 to Apr 2024